AstraZeneca publishes transcript of ERS 2026 investor call and webcast

Reuters2026/09/08 16:17

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

AstraZeneca published a transcript from its “Meet AZN Management: ERS 2026” investor call on Sept. 8, 2026, attended by investors, analysts, and external expert Frank C. Sciurba.
Management highlighted Phase III COPD data for IL-33 antibody tozorakimab from replicate OBERON and TITANIA studies added to standard inhaled care.
Primary endpoint met in former smokers: exacerbation rate ratios 0.71 (p=0.002) in OBERON, 0.66 (p<0.001) in TITANIA.
Key secondary endpoint met in the overall population: rate ratios 0.70 in OBERON, 0.71 in TITANIA, each p<0.001.
Management cited Priority Review in the US with a Q1 2027 PDUFA date, positioning tozorakimab as a potential $5 billion-plus asset.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief on September 08, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

AstraZeneca publishes transcript of ERS 2026 investor call and webcast

You may also like

Crypto prices